Trials / Terminated
TerminatedNCT04024813
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Seladelpar | Capsule(s) administered orally once daily |
| DRUG | Placebo to match Seladelpar | Capsule(s) administered orally once daily |
Timeline
- Start date
- 2019-11-12
- Primary completion
- 2020-01-09
- Completion
- 2020-01-09
- First posted
- 2019-07-18
- Last updated
- 2025-01-16
- Results posted
- 2025-01-16
Locations
10 sites across 3 countries: United States, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04024813. Inclusion in this directory is not an endorsement.